BB Biotech AG/ CH0038389992 /
| - - | Chg. - | Volume | Bid9/4/2023 | Ask9/4/2023 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 57.80EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 2.33 bill.EUR | - | - |
Assets
| 2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | - | - | - | - | - | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Fixed Assets | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Inventories | - | - | - | - | - | ||||||
| Accounts Receivable | - | - | - | - | - | ||||||
| Cash and Cash Equivalents | 10.7000 | 22.1000 | 30.7000 | 6.8000 | 2.8000 | ||||||
| Current Assets | 3,637.8000 | 3,086.8000 | 3,554.6000 | 3,963.1000 | 3,644.1000 | ||||||
| Total Assets | 3,637.8000 | 3,086.8000 | 3,554.6000 | 3,963.1000 | 3,644.1000 | ||||||
Liabilities
| 2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | - | ||||||
| Long-term debt | - | - | - | - | - | ||||||
| Liabilities to Banks | 95 | 185 | 150 | 63 | 355 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 99.1000 | 202.3000 | 161.6000 | 75.6000 | 360.6000 | ||||||
| Share Capital | - | - | - | - | 11.0800 | ||||||
| Total Equity | 3,538.7000 | 2,884.5000 | 3,393 | 3,887.5000 | 3,283.5000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 3,637.8000 | 3,086.8000 | 3,554.6000 | 3,963.1000 | 3,644.1000 | ||||||
Income Statement
| 2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 730 | 5.8000 | 728.2000 | 741.8000 | .0100 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 687.6000 | -471.3000 | 677.5000 | 691.2000 | -404.7000 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | 687.6000 | -471.3000 | 677.5000 | 691.2000 | -404.7000 | ||||||
| Income Taxes | .0800 | .0700 | .0700 | .0800 | .0700 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 687.5000 | -471.3000 | 677.4000 | 691.2000 | -404.8000 | ||||||
Per Share
Cash Flow
| 2017 US GAAP in mill. CHF |
2018 US GAAP in mill. CHF |
2019 US GAAP in mill. CHF |
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 263.5000 | 107.8000 | 215 | 262.4000 | -94.8000 | ||||||
| Cash Flow from Investing Activities | - | - | - | - | - | ||||||
| Cash Flow from Financing | -263 | -93.9000 | -205.2000 | -284.5000 | 91.8000 | ||||||
| Decrease / Increase in Cash | .5000 | 11.3000 | 8.6000 | -23.9000 | -4 | ||||||
| Employees | - | - | - | - | - | ||||||
